



Next generation immunomodulation

www.allegrowbiotech.com

- We are a Hong Kong-based biotech company empowering **high-quality** and **efficient** cell therapies.
- Our advanced biomaterials enable **unparalleled performance** and **versatility** in growing cells.
- Unlocking cell therapy for all immune-related disorders, from **autoimmune diseases** to **cancer**.

Cell Therapy

CAR-T

Modifying T cells to target diseases

Autoimmune diseases

Liquid tumours

50% of currently developing cell therapies

Market size

10.2 billion USD

53% CAGR

CAR-NK

Modifying natural killer cells to target cancers

Tackles both liquid *and* solid tumours

14% of currently developing cell therapies

Comparisons with CAR-T

Safer

Less risk of GvHD, CRS

Harder to culture

Lack of feeder-free systems on the market

Technology Platform

Unparalleled Performance

60% more T cells

470% more NK cells

10% higher T cell viability

Simple Workflow

AimGel beads degrades via hydrolysis

Negates need for de-beading steps

More Control

More central & effector memory T cell subtypes

Control CD8⁺:CD4⁺ ratio of T cells

Less immediate IFN- γ production in T cells reduces risk of cytokine storm

Revenue Streams

Target customer


Product grade

Market size

Stage 1
B2B2C + co-dev

Research institutes/
Academic laboratories

Research use only
(RUO)




400 million USD
in 2024

Stage 2
B2B + royalty sharing

CDMOs/ Biotech /
Pharmaceutical companies

Clinical use
(GMP grade)



100 million USD
in 2024

Product Pipeline

AimTconv

Cytotoxic T Cell

RUO launched

One-to-self

Autoimmune disorders
Cancer treatment



AimNk

Natural Killer Cell

RUO launched

One-to-many

Cancer treatment
Liquid and solid tumors



AimTreg

Regulatory T Cell

Prototype ready

Autoimmune disorders
Organ graft tolerance

Milestones

Funding

1 mil USD award/grant
funds accrued

250,000 USD investment secured
from our home institution, HKUST Efund

Awards

- HKUST Sino1M Champion & Innovation Award
- Hong Kong Techathon Champion
- Jumpstarter Global Pitch Winner
- Geneva International Exhibition of Inventions Gold Medal
- Silicon Valley International Invention Festival Gold Medal

Research Collaboration

- T & NK cells, cell culture company in SE Asia
- NK cells, university research lab in Europe
- T cells, biotech in China
- Dendritic cells & MSCs, biotech in Japan
- Human eggs, biotech in Hong Kong

Technology

- 3 PCT patents pending
- 15+ publications

Accelerator/Incubator/Support Schemes

- HKSTP Incu-Bio Programme
- Technology Start-up Support Scheme for Universities (TSSU)

Financing

We are currently at seed stage,
raising **2** million
USD

**GMP
Setup**

**Marketing
& Growth**

**Research &
Development**

Our Team

Co-founder & CEO

Laurence Lau

- Bioengineering PhD (HKUST)
- Biomaterials
- Drug delivery

BD Lead & Data Scientist

Joel Yu

- Molecular Biomedical Sciences BSc (HKUST)
- Branding & communications
- Data Science

Co-founder & Scientific Advisor

Prof. Ying Chau

- Chemical Engineering PhD (MIT)
- Co-founded 2 biotech
- Leader in biomaterials & drug delivery

Research Scientist

Stella Song

- Life Science PhD (HKUST)
- Cell biology
- Molecular biology

R&D Lead

Fariza Zhorabek

- Bioengineering MPhil (HKUST)
- Cell biology & drug delivery
- Data science

Research Associate

Tedder Huang

- Biomedical Engineering MSc (PolyU)
- Cell biology
- Molecular biology